The Buyout Show with Fexingo · 2026-06-29 · 3 min
Key moments - from our scoring
Substance score
42 / 100
Five dimensions, 20 points each
The eyecare industry has become a major private equity target, with chains like LensCrafters, Pearle Vision, and Visionworks increasingly backed by large PE firms. New Mountain Capital's 2024 acquisition of Visionworks at $1.1 billion exemplifies the trend, signaling deep PE commitment to the sector. The appeal is straightforward: eyecare delivers recurring revenue (annual exams), exceptional margins (frames costing $20 to produce retail for $200+), and massive consolidation opportunity. With approximately 40,000 fragmented independent optometry practices in the US - most single-location owner-operated businesses - PE firms execute classic roll-up strategies by acquiring multiple independents, combining them under management services organizations (MSOs), and centralizing operations like lab work, frame purchasing, and insurance billing to drive down costs and boost margins. For B2B operators in healthcare services, supply chain, or practice management software, this episode reveals how PE is restructuring a previously mom-and-pop industry into a consolidated, professionally managed sector.
PE targets eyecare for three reasons: recurring revenue (annual exams create predictable cash flow), enormous margins (frames costing $20 retail for $200+), and extreme fragmentation - 40,000 independent practices mostly owned by single practitioners, creating a roll-up opportunity.
More than one-third of all optometry practices in the US are now backed by private equity, up from virtually zero ten years ago.
New Mountain Capital, a firm with $50 billion in assets under management, acquired Visionworks in 2024 at an enterprise value of around $1.1 billion, making it one of the largest deals in the eyecare space.
PE firms combine acquired practices under a management services organization (MSO) and centralize operations including lab work, frame purchasing, and insurance billing to reduce costs and increase margins.
Our reviewer’s read on each dimension, with quotes from the episode.
The episode delivers moderately useful structural insights about PE's playbook in eyecare - the three specific reasons (recurring revenue, margins, fragmentation) and the MSO consolidation model are concrete and instructive. However, the overall density is diluted by the self-promotional segment about ad-free funding and lacks deeper operational specifics (e.g., how margins actually change, integration challenges, patient impact).
First, it's a recurring revenue business. People need an eye exam every year or two. That's predictable cash flow. Second, the margins on frames and lenses are enormous. A pair of glasses that costs a lab maybe twenty dollars to produce can retail for two hundred or more.
Private equity firms buy up a bunch of those independents, combine them under a single management company - often called a management services organization, or MSO - and then centralize things like lab work, frame purchasing, and insurance billing.
The framing of PE's entry into eyecare and the three-factor thesis (recurring revenue, margins, fragmentation) are competent but well-worn in PE analysis. There is no contrarian angle, surprising data, or first-principles challenge - just a straightforward explanation of why roll-ups work in fragmented industries, which is standard PE playbook discussion.
There are three things that make eyecare attractive to PE. First, it's a recurring revenue business.
There are something like forty thousand independent optometry practices in the US. Most are single-location, owner-operated. That's a roll-up opportunity.
This is a host-only episode with no guest interview. Lucas and Luna appear to be podcast hosts delivering pre-scripted commentary rather than practitioners or operators with direct M&A or optometry experience. No evidence of actual operating experience in eyecare or PE.
Lucas: So you walk into a LensCrafters or a Pearle Vision or a Visionworks to get your eyes checked.
That's a roll-up opportunity.
The episode includes some concrete numbers: the $1.1 billion Visionworks enterprise value, New Mountain Capital's $50B AUM, ~40k independent practices, one-third PE-backed, $20 production cost vs. $200 retail price. However, it lacks deeper metrics on actual margin improvement post-deal, pricing changes, practice economics (revenue, EBITDA), or post-acquisition performance - stopping at high-level deal structure.
By some estimates, more than a third of all optometry practices in the US are now backed by private equity, up from virtually zero ten years ago.
Back in 2024, a consortium led by New Mountain Capital - a firm with about $50 billion in assets under management - acquired Visionworks at an enterprise value of around $1.1 billion.
Lucas and Luna have a clean, natural back-and-forth rhythm and ask logical follow-up questions (e.g., 'why eyes?'), but the conversation reads scripted and lacks genuine investigation. There are no challenging follow-ups, no pushback on assumptions, no exploration of downsides or complications - just cooperative script-reading that sets up the next segment without probing depth.
Luna: So why eyes? Why is private equity targeting optometry specifically?
Luna: Let's talk about the numbers for a typical independent practice. What does it look like before PE gets involved?
Computed from the transcript - who did the talking, and the words that came up most.
In this episode of The Buyout Show, Lucas and Luna examine why private equity is consolidating the eyecare industry - specifically, the roll-up of optometry practices into giant chains. They focus on the 2024 acquisition of Visionworks by a private equity consortium led by New Mountain Capital at a $1.1 billion enterprise value. Lucas explains the economics: how a single independent optometrist generating $800,000 in annual revenue becomes a 40% EBITDA margin business under a PE-backed platform through centralised labs, bulk purchasing of frames, and patient cross-referrals. Luna pushes back on whether this consolidation actually improves patient outcomes or just inflates contact lens prices. They also touch on the antitrust investigation into EssilorLuxottica, the frame and lens giant that owns LensCrafters and Pearle Vision. By the end, listeners will understand why your eye exam bill keeps going up even though the cost of lens manufacturing has fallen 60% since 2010.
Transcribed and scored by The B2B Podcast Index.
Lucas: So you walk into a LensCrafters or a Pearle Vision or a Visionworks to get your eyes checked. The exam itself takes maybe twenty minutes. You pick out frames you like. You get billed.
A week later you pick up the glasses. That whole experience - it used to be run by a local optometrist who owned their own practice. Now it is increasingly owned by private equity. Luna: And this is happening fast.
By some estimates, more than a third of all optometry practices in the US are now backed by private equity, up from virtually zero ten years ago. Lucas: That's right. And the poster child for this trend is Visionworks. Back in 2024, a consortium led by New Mountain Capital - a firm with about $50 billion in assets under management - acquired Visionworks at an enterprise value of around $1.
1 billion. That deal was one of the largest in the eyecare space and really signaled that private equity was all-in on eyes. Luna: Before we go deeper - and I know we will - it's worth noting that this show is ad-free by design. We choose not to run commercials because we think the conversation is better without them.
If you've found value in these episodes and want to support that choice, the link is buy me a coffee dot com slash fexingo. Nothing else, just that. Lucas: Yeah, it's a small gesture that makes a big difference for us. It keeps the show independent and lets us focus on the numbers.
So thank you to anyone who chips in. Now back to the eyes. Luna: So why eyes? Why is private equity targeting optometry specifically?
Lucas: There are three things that make eyecare attractive to PE. First, it's a recurring revenue business. People need an eye exam every year or two. That's predictable cash flow.
Second, the margins on frames and lenses are enormous. A pair of glasses that costs a lab maybe twenty dollars to produce can retail for two hundred or more. Luna: And the third reason is fragmentation. There are something like forty thousand independent optometry practices in the US.
Most are single-location, owner-operated. That's a roll-up opportunity. Lucas: Exactly. Private equity firms buy up a bunch of those independents, combine them under a single management company - often called a management services organization, or MSO - and then centralize things like lab work, frame purchasing, and insurance billing.
That drives down costs and boosts margins. Luna: Let's talk about the numbers for a typical independent practice. What does it look like before PE gets involved?
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
How Idempotency-Key Design Prevents Payment DisastersThe Developer Tools Podcast with Fexingo · features Luna98 / 100
How Kubernetes Topology Spread Constraints Create Scheduling HotspotsDevOps Daily with Fexingo · features Luna95 / 100
Why Pipeline Velocity Trumps Deal Size Every TimeThe Growth Operator with Fexingo · features Luna95 / 100
Why Enterprise Software Deals Now Include a Vendor AI Model Explainability MandateB2B SaaS Talks with Fexingo · features Luna94 / 100
How B2B Brands Wreck Pipeline with Unsyncroned CRM DataThe Marketing Operator Podcast with Fexingo · features Luna92 / 100
Why Marketing Attribution Misses the Seasonality PatternMarketing Analytics with Fexingo · features Luna91 / 100
Why Private Equity Is Buying Up Dental Support Organizations79 / 100How Private Equity Is Buying Up Dog Daycares84 / 100How Private Equity Is Buying Up Plumbing and HVAC Contractors79 / 100How Private Equity Is Buying Up Urgent Care Centers92 / 100How Private Equity Is Buying Up College Dormitories83 / 100